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Exposure to synthetic mineral ﬁbres (SMF) may occur in a number of workplace scenarios. To protect
worker health, a number of different organisations worldwide have assessed the health risk of these
materials and established workplace exposure limits. This paper outlines the basic principles of risk
assessment and the scientiﬁc methods used to derive valid (justiﬁable) occupational exposure limits
(OELs) and goes on to show how, for SMF, and particularly for refractory ceramic ﬁbre (otherwise known
as aluminosilicate wool, RCF/ASW), the methods used and the associated outcomes differ widely. It is
argued that the resulting differences in established OELs prevent consistent and appropriate risk man-
agement of SMF worldwide, and that development of a transparent and harmonised approach to ﬁbre
risk assessment and limit-setting is required.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Synthetic mineral ﬁbres (SMF) e alternatively known as man-
made mineral ﬁbres (MMMF) e constitute a complex group of
materials including synthetic vitreous ﬁbres (SVF) and certain non-
vitreous materials such as polycrystalline wools (PCW). SVFs
include glass wool, rock/stone wool, slag wool, alkaline earth sili-
cate (AES) wool and aluminosilicate wool (ASW) e also known as
refractory ceramic ﬁbre (RCF). The composition of these materials
differs according to their intended use, though they typically
include silicates and other mineral oxides. They may be manufac-
tured from processed or un-processedmineral rawmaterials; ﬁbres
are normally produced by spinning or blowing themoltenmaterial,
or by a solegel process. Most SMF are used for acoustic or thermalrison), phil@iehconsulting.co.
evan), kkamps@unifrax.com
t.greim@lrz.tu-muenchen.de
Inc. This is an open access article uinsulation, ﬁre protection, reinforcement and ﬁltering applications.
ASW/RCF, along with AES wools and PCW, constitute a family of
ﬁbres known as High Temperature Insulation Wools (HTIW)1 that
are used in specialist industrial high temperature applications such
as furnace linings. Worker exposure by inhalation to these ﬁbres
may occur during ﬁbre production, product manufacture (pro-
cessing) and assembly or installation operations, and during plant
decommissioning or demolition. Exposure of the general public is
generally low and for HTIW is negligible as these materials are not
used in consumer products.
The toxicity of SMF is driven not by chemical constitution but e
because of their ﬁbrous nature e by their size, shape and bio-
persistence, as reﬂected in the so-called ‘3Ds’ paradigm (Brown and
Harrison, 2012; see Section 4.1). This makes the risk assessment
and regulation of SMF rather more complex than for bulk1 For deﬁnitions see: BS EN 1094e1:2008. Insulating refractory products. Ter-
minology, classiﬁcation and methods of test for high temperature insulation wool
products.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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assessed and regulated in different jurisdictions, using ASW/RCF2
as a case example.
The principal objective of this review is to describe and assess
speciﬁcally the approaches that have been applied to SMF, and to
ASW/RCF in particular. We also consider the need for harmo-
nisation of the regulatory processes applied to SMF globally e
including the derivation of OELs for ASW/RCF e to enable consis-
tent and appropriate risk management. The ﬁrst part of the paper
brieﬂy describes some general principles of risk assessment, fol-
lowed by a description of the processes and procedures used to set
occupational exposure limits. The next section looks at ﬁbre-
speciﬁc issues in risk assessment and leads into consideration of
regulatory approaches to SMF in Europe and the USA. Finally,
leading up to the discussion section, there is a detailed ‘case study’
reviewing regulatory approaches to ASW/RCF in different juris-
dictions across the world.
2. Principles of risk assessment
Risk assessment traditionally constitutes three steps e hazard
identiﬁcation, hazard characterisation (or dose-response assess-
ment), and exposure assessment. A fourth step, risk characterisation,
is then applied to integrate the ﬁndings (Finer, 2006; NRC, 2009).
Any attendant uncertainties relating to the ﬁrst three steps are
integrated into the risk characterisation step and it is this infor-
mation that is drawn on for the related, but distinct, process of
deﬁning the necessary risk management measures (RMM) required
to ensure safe use of the substance. Chemical risk assessment
usually incorporates both qualitative and quantitative elements
(Harrison and Holmes, 2006); these are brieﬂy described below.
The process is widely and comprehensively documented elsewhere
by authoritative bodies (for example, EFSA, 2014; COC, 2012a; COC,
2012b; ECHA, 2012a; ECHA, 2012b; WHO, 2010; EFSA, 2009; EC,
2000a; US EPA, 2005).
Hazard identiﬁcation is concerned with identifying the speciﬁc
potential adverse effects of a chemical or mixture through
consideration of its chemical and physical properties in conjunction
with toxicological and toxicokinetic data. Hazard characterisation
entails the evaluation of available data to develop a ‘weight of ev-
idence’ (WoE) argument in support of a link between exposure to a
chemical and the likelihood and severity of any adverse effect (the
apical endpoint). Where a number of different endpoints are
observed, the one that occurs at the lowest exposure level is usually
selected as being ‘critical’ for risk assessment purposes. For the
majority of chemicals it is possible, on the basis of mechanistic
knowledge and available experimental data, to deﬁne a threshold
dose/concentration e such as the ‘no observed adverse effect level’
(NOAEL) or benchmark dose (BMD) e that can be used as the point
of departure (POD)3 (also referred to as Reference Point) for risk
extrapolation (discussed further in Section 2.2). If the dataset does
not allow deﬁnition of an effective ‘no effect’ threshold then, pro-
vided understanding of the toxic mechanism is sufﬁcient to support
the theoretical existence of a threshold, it may be possible to deﬁne
a dose at which only a minimal level of effect is apparent, termed
the lowest observed adverse effect level (LOAEL). Due to the2 ASW/RCF is categorized under the chemical abstracts service registry number
(CAS Number) 142844-00-6 and EC List number 604-314-4. In Europe, under Eu-
ropean Regulation 1907/2006 (REACH), ASW/RCF is deﬁned as a type of UVCB
(chemical substance of unknown or variable composition, complex reaction prod-
ucts and biological material).
3 For most chemicals, POD is expressed as the dose (e.g. mass per kilogram
bodyweight in a given period, e.g. mg/kg bodyweight/day) or as a concentration
(e.g. mg/m3 for atmospheric exposure) to which an organism is exposed.implicitly greater degree of uncertainty associated with a LOAEL, an
additional assessment factor is incorporated into the risk assess-
ment process (Section 2.2).
For a few types of toxic effect (e.g. cancer, mutation and sensi-
tisation), the underlying mechanism may determine that it is
theoretically not possible to establish a threshold below which no
adverse effect will occur; in other words, any exposure to the
chemical might elicit some degree of response (COC, 2012a). Such
chemicals are treated differently from threshold chemicals in the
risk assessment process (Section 2.1). It is to be noted, however,
that the supposed absence of a threshold for genotoxic carcinogens
is increasingly disputed (Greim and Albertini, 2015). Indeed, it can
reasonably be argued that all substances (including genotoxic car-
cinogens) are likely to have some kind of threshold of effect e the
problem is determining where this lies.
Human data for use in risk assessment can be sourced from case
reports, epidemiology, and occupational and clinical studies.
However, each of these sources has certain limitations (Devlin et al.,
2005), and may not be available at all. For these reasons, data from
studies on intact animals are often utilised; these have the
advantage of being designed, controlled and conducted to address
speciﬁc gaps in knowledge or use speciﬁc diseasemodels to speciﬁc
criteria and protocols (e.g. OECD guidelines for the testing of
chemicals4). However, as responses of humans and animals to a
given exposure may be substantially different (both physiologically
and behaviourally), there are always inherent associated un-
certainties when extrapolating from animals to humans. Further,
animal studies have historically investigated dose-response re-
lationships over a much higher concentration range than would be
likely to occur for humans, necessitating extrapolation of the
ﬁndings to lower dose levels, leading to further uncertainty.
Importantly, animal studies can nonetheless provide valuable in-
formation on the Mode of Action (MoA) and Adverse Outcome
Pathway (AOP) to complement the determination of a quantitative
reference point for hazard characterisation (Devlin et al., 2005;
EFSA, 2014). Supporting this aim, a number of in vitro models, in
silico tools (e.g. ((Q)SARs and ‘read-across’ methodologies) and
‘omics’ technologies (transcriptomics, proteomics, metabolomics)
have been developed to investigate toxicokinetic and toxicody-
namic processes at the organism, organ, cell and molecular levels
(described more fully in EFSA, 2014; EC, 2011; Grant et al., 2010; EC,
2009; NRC, 2006; Devlin et al., 2005; Holme and Dybing, 2002).
2.1. Carcinogens and thresholds of effect
With potential carcinogens and mutagens (also sensitising
agents), it is important to consider the MoA by which the chemical
acts and the relationship between dose and adverse response so
that the risk assessment process can allow for the presence or
absence of a threshold. Conventionally, a distinction is made be-
tween ‘genotoxic carcinogenicity’ and ‘non-genotoxic carcinogenicity’
(COC, 2012a), and it is now further recognised that there is a dif-
ference between ‘primary’ and ‘secondary’ genotoxic carcinoge-
nicity, where the latter has a measurable threshold. This is the case,
for example, with certain ﬁbres (see below) where the induction of
reactive oxygen species (ROS) is responsible for a secondary gen-
otoxic effect for which a threshold exists. There are a number of
structured frameworks available for the assessment of the overall
WoE for a postulated MoA (Cohen et al., 2003, 2004; Meek et al.,
2003; Boobis et al., 2006).
For primary (DNA-reactive) genotoxic carcinogens considered4 http://www.oecd.org/chemicalsafety/testing/
oecdguidelinesforthetestingofchemicals.htm.
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damage occur in a linear fashion related to dose, so that any level of
exposure might result in a mutation and hence some measure of
increased risk (SCHER et al., 2009). Under EU Directive 2004/37/EC5
workers' exposure to such chemicals must be prevented by
replacing the carcinogen or mutagen or by using a closed process. If
not technically possible, then riskmust be lowered by ensuring that
exposure of workers is ‘reduced to as low a level as is technically
possible’ (SCHER et al., 2009). Similarly, as complete prevention of
exposure of the general population to carcinogens is not always
feasible, a widely accepted approach to reduce risk from genotoxic
carcinogens is to ensure that levels are controlled so that exposure
is as low as reasonably achievable (ALARA). This may mean pre-
venting exposure entirely or identifying a practical ‘minimal risk
level’ through application of appropriate uncertainty factors to a
POD (e.g. the lower 95% conﬁdence limit of the BMD for a 5%
response over control levels e BMDL5) from dose-response data for
carcinogenicity (Constable and Barlow, 2009; COC, 2012b). In the
US and some European countries, risk from an environmental
genotoxic carcinogen is estimated by the extrapolation of dose-
response data from epidemiology and/or experimental animal
studies to give an estimate of excess lifetime risk (e.g. 1 cancer case
in a population of 1 million). This approach has not been adopted in
the UK as the Committee on Toxicity (COC) considers that the
derived estimate generates a false sense of precision which cannot
be justiﬁed (COC, 2012b).
Non-genotoxic carcinogens are chemicals for which there is no
evidence for a MoA involving genotoxicity as the primary biological
mechanism (COC, 2012a). Many of these chemicals induce tumours
as a consequence of a primary toxic effect (e.g. induction of reactive
oxygen species) for which a threshold dose such as a NOAEL can be
identiﬁed and used as the PoD (Ashby et al., 1996 e cited in COC,
2012a).
2.2. Risk characterisation
The ﬁnal step of the risk assessment process, risk characterisa-
tion, involves ‘the quantitative or semi-quantitative estimate,
including attendant uncertainties, of the probability of occurrence
and severity of adverse effect(s)/event(s) in a given population
under deﬁned exposure conditions based on hazard identiﬁcation,
hazard characterisation and exposure assessment’ (EC, 2000a).
In practice, risk characterisation is usually accomplished by
comparing the POD values (e.g. NOAEL/LOAEL) for the most critical
(sensitive) toxic endpoint with the dose or concentration to which
humans are exposed. Historically it has been common to express
this relationship as the ‘Margin of Safety’ (MoS; i.e. the ratio of the
predicted exposure to the POD, Floyd, 2006), with values < 100
normally interpreted as indicating a need for a more comprehen-
sive evaluation of risk (COC, 2012b).
Alternatively (and now more usually), the experimental POD
may be adjusted to determine an exposure level in humans that
would be ‘acceptable’, through the use of assessment factors
(sometimes termed ‘uncertainty factors’). The derived ‘acceptable’
exposure level may be referred to e depending on the jurisdiction,
and the type and nature of exposure e by terms such as acceptable
daily intake (ADI), tolerable daily intake (TDI), tolerable concen-
tration (TC), minimal risk level (MRL)', reference dose (RfD) or
reference concentration (RfC). Acceptable exposures for workers
are generally termed ‘permissable exposure levels' (PELs), ‘occu-
pational exposure levels’ (OELs) or ‘recommended exposure levels’5 Protection of workers from the risks related to exposure to carcinogens or
mutagens at work.(RELs).
Assessment factors not only account for exposure differences
and limitations in datasets, but also address inherent uncertainties
in the extrapolation process itself (Dourson et al., 1996). Histori-
cally, regulatory systems addressed uncertainty pragmatically, for
example applying a default 100-fold factor to a NOAEL from a
chronic (lifetime) animal study to determine the acceptable expo-
sure for humans (reﬂecting a 10-fold inter-species variability in
sensitivity and 10-fold intra-species variability in sensitivity).
Additional factors might be included because of limitations in
datasets (e.g. from 1- to 100-fold, on a case-by-case basis) when
extrapolating from short-to longer-term durations or if using a
LOAEL rather than a NOAEL as the POD. Further adjustment might
be applied to address severity of effect and reservations on dataset
quality, based on professional judgement (Dourson et al., 1996).
Characterisation of the scientiﬁc basis underlying use of assessment
factors now permits replacement of one or more default values
with chemical-speciﬁc values where speciﬁc toxicokinetic and/or
toxicodynamic data are available (Pieters et al., 1998; Renwick,
1991, 1993, 1999; Renwick and Lazarous, 1998; EVM, 2005).
3. Setting occupational exposure limits
Occupational Exposure Limits (OELs) have been a feature of the
industrialised world for over ﬁfty years. In the EU it is the re-
sponsibility of SCOEL to recommend ‘health based’ OELs where ‘a
review of the total available scientiﬁc database leads to the
conclusion that it is possible to identify a clear threshold dose/
exposure level below which exposure to the substance in question
is not expected to lead to adverse effects’ (SCOEL, 2013). SCOEL
advises that OELs may principally be used ‘to provide standards or
criteria against which measured exposure levels in existing work-
places may be compared in order to ensure that, as far as the cur-
rent state of knowledge permits, control is adequate to protect
health’. However, OELs can also be used for designing new plants
and processes to ensure that they ‘are engineered in such away that
exposures can be controlled at levels which will not damage health’
(SCOEL, 2013).
‘Risk-based’ OELs may be recommended for substances that are
genotoxic, carcinogenic or respiratory sensitisers where, at least
according to current paradigms, it is not possible to deﬁne a
threshold of activity and where it must, therefore, be assumed that
any level of exposure, however small, might carry some ﬁnite risk.
It is the responsibility of the European Commission to set ‘risk-
based’ OELs, which requires consultation with interested parties
(SCOEL, 2013).
OELs may be established using human and/or animal data and
are intended to be protective under realistic workplace exposure
conditions (e.g. by mandating controls on the maximum exposure
during a working day or on peak short-term exposures). Various
approaches exist, such as the previously discussed MoS concept
where, depending on the endpoint considered, a low MoS may
suggest a need for further evaluation. However, in some circum-
stances, and in some organisations/jurisdictions, there may also be
the need to consider aspects such as practicality and achievability.
Depending on the particular socio-economic, legislative and polit-
ical environment, different regulatory regimes may reach some-
what differing conclusions as to what constitutes the appropriate
OEL for a substance, even using the same scientiﬁc evidence.
Since 2010 in the EU, following the implementation of REACH,
the concepts of ‘derived no effect level’ (DNEL) for threshold effects
and ‘derived minimal effect level’ (DMEL) for non-threshold effects
have also been applied to protect workers and other population
groups; the latter is intended to represent an exposure level where
the likelihood that an adverse effect would occur in a population is
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Unlike the traditional OEL setting process, DNEL or DMEL setting for
workers under REACH is a purely risk-based procedure that in-
volves applying various assessment factors to the POD, mostly
involving the use of default values.
DNEL and DMEL values are compared against estimates of hu-
man exposure to decide if the risks are acceptable. For threshold
effects, a risk is considered acceptable if the ratio DNEL:Exposure
(termed the risk characterisation ratio, RCR) is <1. For non-
threshold substances, however, REACH is less clear cut, since the
regulation does not speciﬁcally deﬁne an ‘acceptable’ risk and, in its
guidance, ECHA fails to give a speciﬁc value, instead stating “Based
on these experiences, cancer risk levels of 105 and 106 could be
seen as indicative tolerable risks levels when setting DMELs for
workers and the general population, respectively” (ECHA, 2012a).
This lack of clear guidance has been the subject of criticism
(Puringer, 2011; Losert et al., 2011).
A somewhat different approach continues to be taken by SCOEL
which, under Council Directive 80/1107/EEC as amended by Council
Directive 88/642/EEC, is tasked with developing proposals for
either binding or indicative occupational exposure limit values
(BOELVs or IOELVs respectively); the former refer to situations
where a “no-effect” level of exposure cannot be reliably identiﬁed.
If there is a threshold, health-based OELs are recommended but
‘risk-based’ OELs may be established for non-threshold changes
(particularly genotoxicity, carcinogenicity and respiratory sensiti-
sation). For each substance, SCOEL establishes assessment factors
on a case-by-case basis and distinguishes four types of carcinogen
on mechanistic grounds, namely:
Group A: Non-threshold genotoxic carcinogens e for low-dose
risk assessment linear non-threshold (LNT) modelling is
applied;
Group B: Genotoxic carcinogens e where a threshold cannot be
sufﬁciently established, LNT modelling is used as a default
assumption;
Group C: Genotoxic carcinogens e for which a practical
threshold is supported; and
Group D: Non-genotoxic carcinogens and non-DNA reactive
carcinogens e a true threshold may be established associated
with a NOAEL.
SCOEL seeks to derive health-based OELs for carcinogens in
Groups C and D and, if possible, apply risk-based assessments to
Category A and B substances (Bolt, 2008; Bolt and Huici-Montagud,
2008; Bolt and Degen, 2004; SCOEL, 2013).
As a consequence of the differences in approach between REACH
and SCOEL, safety margins determined through the REACH pro-
cedures are, on average, approximately six-times higher than those
derived by SCOEL. This may be a consequence of its reliance on
default assumptions and ‘rule-based’ processes without the expert
deliberation that is an integral part of the SCOEL approach (Schenk
and Johanson, 2011).
For non-threshold substances (e.g. genotoxic carcinogens), the
risk associated with a particular exposure (e.g. the incidence of
cancers that would arise in a given population; Dorne and Renwick,
2005) can be used to set exposure limits. However this requires a
judgement by policy makers on the disease frequency (e.g. of
cancer) that would be societally acceptable for an exposed group.
Deﬁning such a risk level is a policy matter not a scientiﬁc decision
and, consequently, values are likely to vary between jurisdictions
and depending on the populations affected.
The choice of model used to determine the dose-response
relationship has a critical impact on the risk estimate derived;
linear dose-response assumptions generally givemore conservativeestimates than nonlinear models (NRC, 2006; Gold et al., 2003).
Ideally, model selection should be driven by an understanding of
the underlying MoA.
A summary of the principles that apply in deriving OELs is given
in Table 1.
4. Fibre-speciﬁc considerations
4.1. Toxicological determinants
In the case of ﬁbres, the factors that inﬂuence toxicity and
carcinogenic potency are more complex than simply the chemical
composition andmass of material towhich an organism is exposed.
Instead, the toxicity of a ﬁbre is critically inﬂuenced by the intrinsic
properties of length, diameter and solubility (chemical stability in a
biological environment). The paradigm that describes the potential
for a ﬁbre to produce a toxic response in the lung has been referred
to as the ‘3Ds’, which stands for dose, dimension (where diameter
essentially determines ﬁbre respirability and deposition in the
lung, and length inﬂuences ease of removal by macrophages), and
durability, (or, more properly, ‘biopersistence’, which relates to the
propensity of ﬁbres to dissolve and/or break in the lung milieu;
Hesterberg and Hart, 2001; Maxim et al., 2006; Moore et al., 2001).
Chemical composition of a ﬁbre is generally regarded as important
only in so far as it inﬂuences biopersistence (Brown and Harrison,
2012).
As noted by SCOEL (2011), for humans, ﬁbres with a diameter of
>3 mm are essentially non-respirable, whilst pulmonary deposition
is greatest for ﬁbres of diameter about 1 mm and length about 8 mm.
Clearance of deposited ﬁbres is also a function of length and
diameter, with ﬁbres with a length smaller than the diameter of the
macrophages (c.15e20 mm) being readily phagocytised and
removed by dissolution and/or transport to local lymph nodes.
Longer ﬁbres reaching the alveolar region are cleared more slowly,
depending on their biopersistence. Fibres that are sufﬁciently thin
(<0.1 mm) and durable can penetrate the epithelial surface of the
alveoli and be translocated to the lung parenchyma and pleural
space, where ﬁbres greater than 5 mm may be trapped by their
inability to traverse the parietal stomata, causing inﬂammation
(Lippmann, 2014; Murphy et al., 2013). Inhaled ﬁbres that are
deposited higher up the respiratory tract are removed by the
mucociliary system.
Fibre dimension also plays a critical role in determining conse-
quent pathological responses in the respiratory tract, which are
different according to whether the ﬁbre is in the lung parenchyma
or has been translocated to the pleura. Looking critically at the
relationship between ﬁbre dimension and disease, Lippmann
(2014) found the critical minimum ﬁbre lengths for asbestosis
(interstitial ﬁbrosis), mesothelioma (malignant tumour of the
mesothelium) and lung cancer to be ~2 mm, ~5 mm and ~15 mm,
respectively. With regard to ﬁbre diameter, for asbestosis and lung
cancer, ﬁbreswith diameters>0.15 mmappear to be of predominant
signiﬁcance (as thinner ﬁbres can be more readily cleared via the
lymphatics) whilst for mesothelioma (and other lesions of the
mesothelium), ﬁbres ~<0.1 mm seem to be the most pathogenic.
Overall it can be concluded that pulmonary diseases are caused
predominantly by inhaled ﬁbres thicker than about 0.1 mm and
longer than about 20 mm, while the for pleural diseases, ﬁbres
thinner than ~0.1 mm and longer than ~5 mm are the most
important.
Fibre chemistries that lead to breakage and/or dissolution in the
extracellular lung ﬂuid (pH 7.4e7.5) or within macrophages (pH
4.5e5.0) convey low biopersistence (Bernstein, 2007). As has been
well documented elsewhere (Brown and Harrison, 2012), this
knowledge has led to the development of ﬁbre products such as the
Table 1
Principles and considerations that apply in determining an OEL.
Deﬁnition of OELs OELs are used to provide standards or criteria against whichmeasured exposure levels may be compared in order to ensure that, as far as the
current state of knowledge permits, control is adequate to protect health, or for designing new plants and processes to ensure that they are
engineered in such a way that exposures can be controlled at levels that will not damage health.
Margin of safety (MoS) The relationship (ratio) between the POD value (e.g. NOAEL/LOAEL) for the relevant effect(s) and the dose or concentration to which humans
are exposed. Values below 100 (where the POD is based on animal data) are usually taken to indicate a need for more comprehensive risk
evaluation.
Point of departure (POD) The critical dose level, usually a NOAEL or LOAEL, derived from the key (most relevant/authoritative) study.
NOAEL/LOAEL The ‘no’ or ‘lowest’ observed adverse effect level in an experimental study.
BMD The ‘benchmark dose’ at which a deﬁned level of response occurs (by convention 5 or 10%, depending on the nature of the effect); it is an
alternative to the use of a N/LOAEL as a POD.
T(D)10/T(D)25 For non-threshold carcinogens the BMD may be described as a T(D)10 or T(D)25 indicating the calculated dose for a 10% or 25% tumour
incidence, respectively, using actual dose response data or modelled data assuming for example a linear dose-response relationship.
Assessment factors Deriving an OEL from health effects data invariably requires the application of ‘assessment factors’ to account for uncertainty in the process,
particularly in relation to various extrapolations and assumptions that need to be made, for example in using animal data to predict human
risk.
DNEL The ‘derived no-effect level’ for threshold substances, calculated for REACH purposes according to ECHA guidance (Chapter R.8). This
guidance gives various default values for the assessment factors that are to be applied, differentiating between workers and the general
public and for different routes of exposure. An airborne DNEL for workers may be taken as equivalent to an OEL.
DMEL The ‘derived minimal effect level’ e similar in principle to a DNEL but calculated differently and applied to substances with non-threshold
effects, such as genotoxic carcinogens. A DMEL for workers may be taken as equivalent to an OEL.
MoA The ‘mode of action’ of a substance that indicates whether a threshold or non-threshold approach should be used in establishing the DNEL/
DMEL and/or OEL. For non-threshold substances a so-called ‘risk-based’ OEL is set.
Acceptability of
risk/tolerable risk
For threshold effects, a risk is usually considered acceptable if the ratio DNEL:Exposure (the risk characterization ratio) is less than 1. For non-
threshold substances such as genotoxic carcinogens, risk levels ranging between 103 and 106 for workers and/or the general public may be
considered ‘tolerable’.
IOELV An ‘indicative occupational exposure limit value’ is a health-based limit conventionally established only for substances for which it is
possible to establish a threshold or a no-effect level considered to be protective of health. They are, in essence, OELs recommended by SCOEL.
BOELV A ‘binding occupational exposure limit value’ may be formally established by the Council and European Parliament in cases where an
appropriate limit of exposure can be identiﬁed based on risk as well as socio-economic impact assessment. BOELVs primarily apply to non-
threshold substances covered by the EC Carcinogens and Mutagens Directive (CMD), and are also recommended by SCOEL.
WoE ‘Weight-of-evidence’ is an approach involving the assessment of the strengths and weaknesses and relative weights of different pieces of
information. It requires expert judgement and is inﬂuenced by a variety of factors including data quality and consistency, nature and severity
of effects, and relevance. Reliability, relevance and adequacy for purpose must always be taken into account in the WoE approach.
P. Harrison et al. / Regulatory Toxicology and Pharmacology 73 (2015) 425e441 429AES wools that have low biopersistence and therefore are less
hazardous to the lung.6 Dr Geoff Pigott e personal communication.
7 IARC (2002). IARC monographs on the evaluation of carcinogenic risks to
humans. Vol.81. Man Made Vitreous Fibres. International Agency for Research on
Cancer, Lyon, France. ILSI Working Group (2005). Testing of ﬁbrous particles: short-
term assays and strategies. Inhal. Toxicol. 17: 497e537. NIOSH (2006). Criteria for a
Recommended Standard. Occupational Exposure to Refractory Ceramic Fibres. Na-
tional Institute for Occupational Safety and Health, Atlanta, Georgia. NRC (2000).
Review of the US Navy's Exposure Standard for Manufactured Vitreous Fibres. The
National Academies Press, Washington, DC.4.2. Toxicological testing of ﬁbres
Standard toxicological assessment of ﬁbrous materials is per-
formed using inhalation, intratracheal and/or intrapleural/intra-
peritoneal methodologies. In the absence of human
epidemiological data, inhalation testing in experimental animals is
generally regarded as the ‘gold standard’ for this purpose. Intra-
tracheal experiments are known to suffer from problems of ﬁbre
agglomeration during dosing and of irregular deposition of the test
material in the lung (the ‘bolus effect’) but the technique is still
recommended by some regulators for biopersistence testing, for
example.
Despite the use of the intraperitoneal (IP) test by certain regu-
latory authorities for cancer risk assessment purposes (see Section
5.2.1), results derived by this procedure are of limited value
compared to ﬁndings from inhalation tests for assessing the
possible carcinogenicity of inhaled substances in humans, princi-
pally because the IP test bypasses the animal's respiratory system.
The lung is an extremely efﬁcient particle ﬁltering/clearance sys-
tem, so that while certain sized particles can and do reach the deep
lung, the translocation of ﬁbres from the lung parenchyma to the
pleural space (by mechanisms that have not yet been fully eluci-
dated) involves a certain ‘dwell time' which is likely to result in the
modiﬁcation (e.g. by dissolution and/or fragmentation) of the
number and nature of ﬁbres that eventually reach the pleura. This
will further attenuate any relationship between number/type of
ﬁbres inhaled and those reaching the pleural (and/or peritoneal)
mesothelium. Further, ﬁndings based on the delivery of ﬁbres direct
to the peritoneum are of questionable relevance to human risk
assessment for parenchymal lung cancer. In addition it is possible,or in some cases likely, that the dose delivered to the mesothelium
may contain non-respirable ﬁbres.6 Given that such coarse ﬁbres
are established irritants and that irritation is a well-established
tumour promoting mechanism, their presence is likely to
confound the IP test. Together, such arguments suggest that ﬁbre
hazard potential determined by IP tests is of little or no value for
inferring human risk; suggestions that IP testing is more sensitive
and superior to inhalation testing run counter to the reasoned as-
sessments of several authoritative bodies (e.g. IARC, ILSI, NIOSH and
NRC)7 which concluded that inhalation studies constitute the best
available model for assessing human risks from exposure to ﬁbres,
although it is understood that reservations exist in some quarters
about results obtained with asbestos in rodent studies compared to
the human experience (e.g. Wardenbach et al., 2000).
4.3. The measurement and characterisation of ﬁbres
Throughout this paper, reference to a ‘ﬁbre’ generally means a
standard ﬁbre as deﬁned (for monitoring/measurement purposes)
by theWorld Health Organization. A ‘WHO ﬁbre’ is any particle that
has a length greater than 5 mm, a diameter less than 3 mm and
length:diameter ratio greater than 3:1. The standard method of
measuring and counting ﬁbres uses phase contrast optical micro-
scopy (PCOM) although this method is poor at identifying ﬁbres
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tween different ﬁbre types. Also the PCOM protocol does not pro-
vide length and diameter distributions for visualized ﬁbres longer
than 5 mm (Lippmann, 2014). Thus the most hazardous ﬁbres e if
present e may not be counted. These important issues of ﬁbre
identiﬁcation and quantiﬁcation can have considerable practical
implications for routine accurate monitoring of health-relevant ﬁ-
bres in the workplace (Lippmann, 2014). Further, it must be un-
derstood that the WHO deﬁnition covers a very wide range of ﬁbre
sizes and thus respirability e for example, ﬁbres of 0.1 mmdiameter
will be considerably more respirable than thicker ﬁbres of 3 mm
diameter.
It is assumed that ﬁbre count ﬁgures referred to by the various
regulatory/standard-setting bodies in the following sections reﬂect
the WHO deﬁnition and the use of PCOM (rather than electron
microscopy) for measurement purposes.9 Technical Rules for Hazardous Substances: Directory of carcinogenic, mutagenic
or teratogenic substances (TRGS 905). Version: July 2005, Committee on Hazardous
Substances e AGS management e BAuA ewww.baua.de. Available at: http://www.
dkfg.de/pdf/vorschriften/TRGS-905-Stand-Juli-2005-engl.pdf (accessed July 2015).
10 Announcement on Hazardous Substances: Risk ﬁgures and exposure-risk re-
lationships in activities involving carcinogenic hazardous substances. Announce-
ment 910, Version June 2008, Ausschuss für Gefahrstoffe e AGS-Gesch€aftsführung
e BAuA e www.baua.de.
11 Technical Rules for Hazardous Substances: Risk-related concept of measures for5. Regulatory risk assessment of SMF in Europe
5.1. Current classiﬁcations for SMF
In the EU, man-made vitreous (silicate) ﬁbres were classiﬁed
under the ‘Dangerous Substances Directive’ 67/548/EEC (as amen-
ded by 97/69/EC) as carcinogenic unless they are continuous (ﬁla-
mentous) thick ﬁbres (with length-weighted geometric mean
diameter less two standard errors greater than 6 mm). Thinner ﬁ-
bres containing more than 18% by weight of alkaline and alkaline
earth oxides8 may also be exonerated from classiﬁcation if certain
bioassays demonstrate low biopersistence and/or lack of pathoge-
nicity, as described in Note Q of the Directive (which refers to the
assessment of short-term biopersistence by inhalation or intra-
tracheal instillation, and of carcinogenicity by appropriate IP tests
or suitable long-term inhalation tests) (Brown and Harrison, 2012).
The biopersistence protocols incorporated into Note Q of the
Directive were developed and standardised by the European
Commission using the results from chronic inhalation studies
(Bernstein and Riego-Sintes, 1999). In line with the recognition of
the importance of biopersistence in ﬁbre carcinogenicity, Note Q
mandates that ﬁbres should not be classiﬁed as carcinogenic where
short-term inhalation biopersistence testing establishes that the
weighted clearance half-time for ﬁbres longer than 20 mm is less
than 10 days e or less than 40 days in the case of intra-tracheal
testing (Bernstein, 2007). These rules have now been transferred
to the EU Classiﬁcation, Labelling and Packaging (CLP) regulation.
It is noteworthy that the adoption of this formal Directive (and
latterly the CLP regulation) served as a major stimulus to European
SMF manufacturers to develop, test and market ﬁbres that had low
biopersistence and could meet the criterion for exoneration from
identiﬁcation as a carcinogen in the absence of data from chronic
bioassays. The development of a regulatory paradigm that avoided
the need for conducting long-term studies using large numbers of
animals was also consistent with the growing movement around
the world to minimise the number of laboratory animals used in
research (Hesterberg et al., 2012).
However, there remains some concern about how the ‘18%’
formula in Note Q was derived and whether it is truly justiﬁed.
Bellmann et al. (2010), for example, investigated the chemical
composition of glass and stone wools in the light of the then
available toxicity database. Data for about 60 different ﬁbres
investigated in the intra-tracheal biopersistence test standardised8 i.e. Na2O þ K2O þ CaO þ MgO þ BaO >18% by weight; such ﬁbres are termed
‘Mineral wool’ in the Directive. The scientiﬁc basis for this compositional criterion is
not documented.in the EUwere analysed, leading to a model that enabled prediction
of half-times based on chemical composition. The authors
concluded, however, that for regulatory purposes the model is not
sufﬁcient to replace biopersistence tests completely, and the
question still remains about the scientiﬁc derivation and justiﬁca-
tion of the chemical composition deﬁnition in Note Q.
In Germany (see also Section 5.2.1), additional regulations apply
to ﬁbrous dusts as speciﬁed under technical guidance on worker
protection TRGS 905,9 which contains a list of substances that can
release dusts classiﬁed as carcinogenic; it includes dusts generated
from substances or preparations that may not have been classiﬁed
by the EU. This document gives criteria for assessing the carcino-
genicity of ‘inorganic ﬁbrous dusts’ e including vitreous WHO ﬁ-
bres. The rules in the document indicate that ﬁbres can be classiﬁed
by conducting IP carcinogenicity tests (with speciﬁed numbers of
ﬁbres to be injected) or by determining in vivo biopersistence in
intratracheal instillation tests.
5.2. Some speciﬁc national approaches to the risk assessment of
SMF in Europe
5.2.1. The German ‘Exposure-risk relationship’ concept
German authorities have adopted a system based on quantita-
tive risk assessment in which deﬁned levels of ‘acceptable risk’ are
used to determine OELs for carcinogens. This approach, champ-
ioned by the German Committee on Hazardous Substances e
Ausschuss für Gefahrstoffe (AGS), an advisory body of the Federal
Ministry of Labour and Social Affairs concerned with occupational
safety and health measures e is known as the Exposition-Risiko-
Beziehung (ERB) or exposure-risk relationship (ERR) concept. It
was described in detail in AGS ‘Announcement 910’10 and accom-
panying guidance documents, and subsequently published in TRGS
910.11 This methodology, which has been applied to ASW/RCF (see
Section 8.2.2), is suggested by these bodies as a means of estab-
lishing exposure-risk relationships for carcinogens, making the risk
management of such substances manageable and allowing the
setting of exposure limits incorporating societal judgements of the
acceptability of risk (see also Wardenbach et al., 2000). However,
aspects of both its underlying scientiﬁc assumptions and practical
implementation are open to criticism. For example, the document
notes that ‘no occupational exposure limit can currently be derived
for the vast majority of carcinogenic substances’ but paradoxically
makes no distinction between threshold and non-threshold
(directly genotoxic) carcinogens. The Annex in which the term
‘risk’ is deﬁned refers to ‘health damage’ and fails to clarify if the
risks being considered relate speciﬁcally to cancer or the likelihood
of any ‘health damage’. Also, where asbestos is given as an example
of implementation of this approach, no differentiation is made
between the different forms of asbestos, despite it being now well
established that amphiboles are more potent than chrysotile (e.g.
see Berman and Crump, 2008; Bernstein et al., 2013).activities involving carcinogenic hazardous substances. TRGS 910. Version: February
2014, Committee on Hazardous Substances e AGS management e BAuA e www.
baua.de. Available at: http://www.baua.de/en/Topics-from-A-to-Z/Hazardous-
Substances/TRGS/pdf/TRGS-910.pdf?__blob¼publicationFile&v¼6 [accessed July
2015].
14 Technical Rules for Hazardous Substances: Demolition, reconstruction and
maintenance work with biopersistent mineral wools (TRGS 521). Version: January
2011, Committee on Hazardous Substances e AGS management e BAuA e www.
baua.de. Available at: http://www.baua.de/en/Topics-from-A-to-Z/Hazardous-
Substances/TRGS/pdf/TRGS-521.pdf?__blob¼publicationFile&v¼2 (accessed July
2015).
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‘Exposure-risk relationship for man-made ﬁbres’ contained in the
AGS document ‘ERR (exposure-risk relationship) for aluminium sili-
cate ﬁbres12 ewhich is a reworking of ‘Exposure-risk relationship for
synthetic mineral ﬁbres’ produced by the AGS Working Group on
Fibres and Dusts (AKF&S).13 This sets out to establish an exposure-
risk relationship for man-made mineral ﬁbres (MMMFs), which
forms the basis for the ERR for aluminium silicate ﬁbres (see also
Section 8.2.2). In this document, ‘risk’ is said to be the likelihood
that additional ‘adverse effects’ will occur in exposed compared to
non-exposed persons. This is unhelpful given that the normal
conventions of quantitative risk assessment and societally accepted
levels of risk usually refer to the risk of death or serious injury
rather than unspeciﬁed ‘adverse effects’. The starting point for
deriving exposure-risk relationships here is the quantitative risk
assessment of asbestos (all types combined), derived from epide-
miological studies. The authors state that it was not appropriate to
reference epidemiological ﬁndings on MMMFs given that essen-
tially only non-positive ﬁndings have been obtained. This reveals a
clear underlying bias by the authors in presuming that MMMFs are
necessarily carcinogenic to humans despite the lack of any epide-
miological evidence to support this view (e.g. see Greim et al.,
2014). The assessment also makes the unfounded assumption
that tests using IP injection permit a comparative assessment of the
potential effects of asbestos and different types of MMMF (see
Section 4.2). While correctly documenting the essential principles
and determinants of ﬁbre toxicity (i.e. length, diameter and bio-
persistence), the assessmentmakes a questionable assumption that
IP tests are able to accurately e and in a quantitative fashion e
discriminate ﬁbres in relation to their carcinogenic potency in the
lung. Moreover, the data concerning mesothelioma induction after
IP injection is taken from a 1994/95 Annual Report of the German
Medical Institute for Environmental Hygiene, which is unpublished
and therefore not peer-reviewed.
Various calculations are presented for different size ranges of
ﬁbres. It is well known that length is important and that longer
ﬁbres (L > 20 mm) are notably more pathogenic than short ﬁbres.
Whilst acknowledging that if only ﬁbres longer than 20 mm are
taken into account the calculated risks for MMMFs relative to
crocidolite are smaller, the authors choose to regard this as irrele-
vant and instead base their risk assessment on ‘WHO ﬁbres’.
Overall, this is likely to result in risk estimates that are too high,
perhaps by a factor of 10. Furthermore, the use of the BMD10/T10 in
a quantitative risk assessment approach assumes an (unproven)
straight-line relationship between dose and cancer induction and is
fundamentally inappropriate for application to ﬁbres that exhibit a
threshold of effect.
Methods of ﬁbre preparation are likely to be critical to the re-
sults obtained in IP tests. The protocol involves injection of an
entire ﬁbre sample into the peritoneum (as a model for the pleural
mesothelium) whereas, after inhalation, ﬁbres will naturally un-
dergo varying degrees of size selection, attenuation and commi-
nution before reaching the pleural space (see Section 4.2). This
further emphasises the problems with the IP test and the non-
physiological nature of the exposure involved.
Arguments in the document comparing the calculated risks
with epidemiological data appear to suggest that the predictions of
the proposed approach cannot be veriﬁed by epidemiological study.
It would thus appear that the proposed exposure-risk method e or12 Exposure-risk relationship for aluminium ﬁbres. Committee on Hazardous
Substances (AGS) e AGS Management e BauA e www.baua.de. May 2010.
13 WG on Fibres/Dust 12.12.07, Annex 6, Exposure-Risk Relationship for SMF,
version dated 23.11.07.at least its application to MMMF e is not testable using the scien-
tiﬁc method. It can certainly be argued that the occupational risks
estimated using the proposed method are highly uncertain, to the
point of being speculative, and the range of estimates for any
particular MMMF could vary by huge factors.
Considering the ERR approach more generally in relation to
other adopted approaches (as used, for example, by SCOEL) for
substances for which a non-genotoxic or a threshold genotoxic
mechanism can be shown to be responsible for the carcinogenic
process, there is no need and, indeed, no advantage, to be gained
from seeking to calculate risk estimates as the basis for setting
limits. Rather, health-based methods involving the initial deﬁnition
of a no-effect level (NOAEL) are appropriate.
Unfortunately, despite the inappropriateness of the AGS/ERR
approach for MMMF, this methodology has had a profound inﬂu-
ence on the development of German ‘Technical Rules for Hazardous
Substances’. Thus, TRGS 52114 (Demolition, reconstruction and
maintenance work with biopersistent mineral wools) has been
applied to workers involved in demolition, reconstruction and
maintenance work with biopersistent mineral wools where dusts
classiﬁed as carcinogenic are released, and TRGS 55815 (Activities
involving high-temperature wool) has been applied to the protec-
tion of workers and other persons engaged in activities involving
ﬁbrous dusts classiﬁed as carcinogenic that may be released during
activities involving high temperature (insulation) wools.
5.2.1.1. TRGS 521. This lists a number of activity scenarios within
three different ‘exposure categories’, linking these with certain
ﬁbre dust concentrations to drive the requirement for protective
measures. The ‘trigger’ concentration is 50,000 ﬁbres/m3 e or
0.05 f/ml e which is equivalent to that for asbestos and far stricter
than OELs applied by other jurisdictions to SVF. This makes con-
forming to the limit highly problematic and requires exposure
monitoring to limits far beneath those for most other countries.
5.2.1.2. TRGS 558. This applies to ASW/RCF (see Section 8.2.2) but
also states, without justiﬁcation, that it similarly applies to PCW. It
is stated that ‘according to the current state of scientiﬁc knowledge
it is not possible to discount a risk of cancer when these ﬁbre dusts
are inhaled’. As with TRGS 521, this document also establishes three
levels of exposure category (low, medium and high ‘risk areas’),
referring to the concept of ‘graduated risk control’ for carcinogenic
substances as described in TRGS 910. These different exposure-risk
levels are based on the deﬁnitions of ‘acceptable’ and ‘tolerable’
risk16 and the equivalent ﬁbre concentrations that are set out in the
document ‘Exposure-risk relationships for synthetic mineral ﬁbres’.
For each different ‘risk level’ a number of worker protective mea-
sures are mandated. This document is ﬂawed not by its intentions
or the suggested protective and precautionary measures, but by the
assumption, driven by TRGS 910 and the ‘exposure-risk relation-
ships for synthetic mineral ﬁbres’ document, that HTIW (specif-
ically ASW/RCF e see Section 8.2.2 e and also PCW) is as potently15 Technical Rules for Hazardous Substances: Activities involving high-
temperature wool (TRGS 558). Version: March 2011, Committee on Hazardous
Substances e AGS management e BAuA ewww.baua.de. Available at: http://www.
baua.de/en/Topics-from-A-to-Z/Hazardous-Substances/TRGS/pdf/TRGS-558.pdf?
__blob¼publicationFile&v¼2 (accessed July 2015).
16 The three levels relate to exposure risks that are below the ‘acceptable’ risk, or
between ‘acceptable’ and ‘tolerable’, or above ‘tolerable’.
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is no justiﬁcation.
5.2.2. UK HSE
UK occupational exposure limits e now named “Workplace
Exposure Limits” (WELs) e are listed in the ofﬁcial UK Health and
Safety Executive (HSE) guidance document EH40 (HSE, 2011). The
current WELs for MMMF (machine-made mineral ﬁbre17 (except
for ‘refractory ceramic ﬁbres and special purpose ﬁbres’) are spec-
iﬁed as being 5 mg/m3 (8-h TWA of inhalable dust) and a ﬁbre
number concentration of 2 ﬁbres/ml. The equivalent gravimetric
and ﬁbre number WELs for ‘refractory ceramic ﬁbres and special
purpose ﬁbres’ are 5 mg/m3 and 1 ﬁbre/ml, respectively (see Sec-
tion 8.2.4).
EH40 states that “Machine-made (formerly ‘man-made’) min-
eral ﬁbres are deﬁned as man-made vitreous (silicate) ﬁbres with
random orientation with alkaline oxide and alkali earth oxide
(Na2O þ K2O þ CaO þ MgO þ BaO) content greater than 18% by
weight. Neither the gravimetric limit nor the ﬁbres in air limits
should be exceeded. Fibre concentrations of MMMFs must be
measured or calculated by a method approved by HSC” (UK Health
and Safety Commission).
The gravimetric exposure limit (WEL) for mineral wool ﬁbres in
the UK is equivalent to 50% of the gravimetric concentration that is
the reference point for further risk management consideration for
generic dusts for which no speciﬁc WEL is set.
6. Regulatory risk assessment of SMF in the USA
The regulatory processes of the USA differ fundamentally from
those of the EU. In the EU, the initial premise for classiﬁcation is
based on the intrinsic hazard of the material, with the speciﬁc
objective of determining what protective measures are required
during normal handling and use. In the USA, in contrast, the EPA
uses a risk-based evaluation considering both hazard and exposure
data and applying ‘weight of evidence’ considerations (Bernstein,
2007).
As of 2003, the US EPA had not classiﬁed the potential carci-
nogenicity of glass wool, continuous ﬁlament glass, rock wool, or
slag wool, but assigned ASW/RCF to Group B2 (probable human
carcinogen) based on the results of animal studies (Bernstein,
2007).
The US EPA advises that “when available data are insufﬁcient to
establish themode of action for a tumor site andwhen scientiﬁcally
plausible based on the available data, linear extrapolation is used as
a default approach” and “A nonlinear approach should be selected
when there are sufﬁcient data to ascertain the mode of action and
conclude that it is not linear at low doses and the agent does not
demonstrate mutagenic or other activity consistent with linearity
at low doses”.
7. Principles of precaution, feasibility and achievability
relevant to the risk assessment of ﬁbres
The precautionary principle came to form a fundamental
element of German environmental law in the early-1970s (Tickner
et al., 1998). Internationally, a pivotal step was its adoption in the
1992 Rio Declaration from the United Nations Conference on
Environment and Development (Agenda 21; Tickner et al., 1998).
The EC recommends that ‘the precautionary principle should be
used by decision-makers when deciding on risk management17 More commonly referred to as Man-Made Mineral Fibre or Synthetic Mineral
Fibre (SMF).policy but should not be confusedwith use of assessment factors by
scientists during risk assessment’ (EC, 2000b). Some EU Member
States, including France, Sweden and Denmark, have adopted the
principle fairly extensively (Tickner et al., 1998), whilst several
other jurisdictions apply different interpretations of the principlee
for example, New Zealand (Cameron, 2006) and Australia (Gullett,
2000).
For the precautionary principle to be invoked, the EC considers
that three preliminary conditions must be met: (i) there has been
identiﬁcation of potentially adverse effects; (ii) the scientiﬁc data
available has been evaluated; and (iii) there is an understanding of
the extent of scientiﬁc uncertainty surrounding the concern. In the
case of ﬁbrous material and, increasingly some nanomaterials (e.g.,
Hansen et al., 2013) there have been pressures to adopt an extreme
precautionary approach; this has frequently resulted in ill-founded
analogies with asbestos being drawn. Such arguments have ignored
the fact that much has been learned about the physico-chemical
properties of different types of ﬁbre and the way these inﬂuence
the underlying mechanisms of toxicity.
An important factor inﬂuencing the successful implementation
of risk management decisions is that the ‘acceptable’ level derived
by risk assessment should be realistic and able to be substantiated.
Thus, it is important that the feasibility of achieving a desired
exposure level is considered and that it is possible to measure
exposure in the workplace to a sufﬁciently high degree of accuracy
to demonstrate whether or not control has been achieved. Whilst
the technical challenges for chemicals with a threshold mechanism
(where under REACH a DNEL would be set) are more likely to be
achievable, in the case of non-threshold chemicals the magnitude
of the challenge may be considerably greater. In such circum-
stances, use of the ALARA concept remains appropriate in order to
achieve an acceptable risk by adopting reasonably achievable
control measures in a manner that balances risks and beneﬁts. The
reasonableness of the cost of control is generally evaluated using
various technological criteria, such as ‘best available control tech-
nology’ (BACT) or ‘best practicable control technology’ (BPCT;
Shortreed et al., 2003). Indeed, since REACH does not overrule the
requirements of the Carcinogens and Mutagens Directive (CMD,
2004/37/EC), use of the ALARA approach to controlling workplace
exposure remains appropriate in the EU (ECHA, 2012b).
8. Case study: regulatory approaches to assessing risk for
ASW/RCF in different jurisdictions
8.1. USA
8.1.1. NIOSH and OSHA
The US National Institute for Occupational Safety and Health
(NIOSH) is a non-regulatory federal agency responsible for con-
ducting research and making recommendations for the prevention
of work-related injury and illness (NIOSH, 2013). It is located as part
of the Centers for Disease Control and Prevention (CDC) within the
U.S. Department of Health and Human Services, and can act as the
“scientiﬁc research arm” of the Occupational Safety and Health
Administration (OSHA). OSHA, itself part of the US Department of
Labor, is primarily responsible for developing and enforcing occu-
pational safety and health regulations (OSHA, 2011). Generally in
the US, a risk of 1 106 is applied as the ‘de minimis’ criteria when
risks to the general public are being assessed. However, when
considering occupational exposure, OSHA will not introduce regu-
lation of a substancewhere the incremental lifetime cancer risk to a
worker exposed for his entire working lifetime is estimated to be
substantially below 1  103 (Adler, 2007). Interestingly, experi-
ence indicates that not dissimilar risk values tend to be applied in
the EU (e.g. EMA, 2006).
18 See http://www.htiwcoalition.org/index.html.
19 Letter from D. Michaels (OSHA) to D. Hadden (HTIW Coalition) on RCF PSP 2012
Agreement. Available online at: ﬁle:///C:/Users/Ron/Dropbox/Michaels%20to%
20Hadden%20RCF%20PSP%20July%202012.pdf. Last accessed on March 9th, 2015.
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ASW/RCF (OSHA, 2015), in 1999 OSHA established a PEL (8-h TWA)
of 1.0 f/cc (1 f/ml) for ﬁbreglass and mineral wools (glass wool, rock
wool and slag wool) under a voluntary agreement with industry
termed the Health and Safety Partnership Program (HSPP) (OSHA,
1999; ATSDR, 2004; Marchant et al., 2002). The HSPP featured the
newly recommended PEL, training programmes, medical moni-
toring, engineering control resources, and information on appro-
priate respirator use. Later, OSHA (2001) also established a 5mg/m3
(respirable) limit for all synthetic vitreous ﬁbres, as part of regula-
tions relating to inert or nuisance dusts, and a 15 mg/m3 limit in
relation to total dust, thatwere intended for use bygeneral industry.
As with ﬁbreglass and mineral wools, the refractory ceramic
ﬁbre industry entered into several long-term voluntary agree-
ments with various government agencies (e.g., OSHA, NIOSH and
EPA). Collaborative work began as a ﬁve-year consent agreement
with EPA in 1993 that was included in the industry's Product
Stewardship Program (PSP). Upon completion of the EPA agree-
ment, the industry continued its voluntary stewardship program
under OSHA oversight. The PSP was designed to speciﬁcally
address the RCF-type of synthetic vitreous ﬁbre (ATSDR, 2004;
RCFC, 2015a). Under the PSP, in the absence of a lower speciﬁc
regulatory limit, industry adopted a ‘recommended exposure
guideline’ of 0.5 f/cc (8-h TWA) that, rather than being risk based
per se, was developed by considering what would be a realistic,
generally feasible level that could be attained through use of
workplace engineering controls (RCFC, 2015a). The PSP also
included ongoing medical monitoring, medical surveillance,
development of engineering controls, use of an explicit respirator
policy, preparation of handling guidelines, and training. Since the
program began in the early 1990s, the weighted average of all
occupational exposures to RCF in the US for both manufacturers
and customers working with RCF has decreased to around 0.2 f/ml
(Maxim et al., 2008).
In 2006, NIOSH published a Criteria Document on RCF (NIOSH,
2006) in which a recommended exposure limit (REL) of 0.5 ﬁbres
per cubic centimetre (f/cm3) TWA was proposed for shifts of up to
10-hr during a 40-hr working week. This level was stated as being
sufﬁcient to minimize risks of lung cancer and irritation of eyes and
upper respiratory system; it was noted however, that at this level
there remained some degree of cancer risk and therefore it was also
recommended that there should be continued effort to reduce
exposure to <0.2 f/cm3.
To inform their recommendation, NIOSH conducted an extensive
review of available experimental and human data, and concluded
that epidemiological studies indicate that current occupational
exposure to ASW/RCF is not associated with an increased risk of
pleuralmesotheliomaor lung cancer.However, forworkers involved
in its manufacture, historical associations had been found between
the airborne exposures then occurring and a range of pathological
changes, including pleural plaques, impairment of pulmonary
function and increase in respiratory symptoms and conditions
(pleurisy, dyspnea and cough). Also, increased risk of skin and eye
irritation had been observed historically, even after adjusting for
smoking and non-ﬁbrous dust co-exposure. Though there was evi-
dence of possible interactions between the risk of co-exposure to
ASW/RCFand cigarette smoke, the effect onpulmonary functionwas
still detectable in non-smoking females. Experimentally, inhalation
of ASW/RCF was noted to have caused lung cancer in rats and me-
sothelioma in hamsters, though interpretation of these ﬁndingswas
difﬁcult due to the issue of co-exposure to ﬁbres and non-ﬁbrous
respirable particles in these experiments (see Hesterberg et al.,
1995; Brown et al., 2000, 2005). Other experimental effects re-
ported included enzyme induction, haemolysis and, possibly,
impairment of cell viability and inhibition of proliferation, as well aseffects on mediator release and induction of free radicals, micro-
nuclei, polynuclei, chromosomal breakage and hyperdiploid cells.
When determining their recommended REL for ASW/RCF, it is
evident that NIOSH adopted a pragmatic approach in that they drew
on the toxicological evidence fromhuman and experimental studies
but also considered evidence on the extent to which ASW/RCF
exposure could now be controlled for various workplaces and ac-
tivities. The resultant REL is therefore considered to be “achievable
for most workplaces where RCFs or RCF products are manufactured,
used, or handled”. When considering the residual risk of lung cancer
at the recommended REL, an estimate of 0.073e1.2 cases per 1000
wasmade byextrapolation froma number of published riskmodels.
Mesothelioma risk at this exposure standard was considered to be
uncertain due to data limitations, though it was suggested to be
somewhat lower than that for lung cancer risk on the basis of the
lack of any evidence that mesothelioma occurred in workers
exposed to ASW/RCF and as pleural plaques were considered less
likely to develop in workers with lower exposure. Nonetheless,
NIOSH suggested that all reasonable effort should be made to
further reduce worker exposure to 0.2 f/cm3 or below, the level at
which lung cancer risk was suggested to be 0.03e0.47 cases per
1000 (equating to a further reduction in cancer risk of some 40%).
Following publication of the NIOSH Criteria Document, OSHA
expressed their support for the continuation of the voluntary
stewardship program, initially established with the Refractory
Ceramic Fibres Coalition (RCFC) (and subsequently with the High
Temperature Insulation Wool (HTIW) Coalition18) as a means of
achieving continued reductions in workers' exposure to ASW/RCF
(OSHA, 2007; HTIWC, 2015). The most recent version of the pro-
gram (2012e2017) continues the efforts to reduce workers' expo-
sure to ASW/RCF (Michaels, 2012 19; HTIWC, 2015). Consequently,
OSHA has not proposed a change to the standards it had previously
established. However, California's Occupational Safety and Health
Standards Board has since adopted a permissible exposure limit
(PEL) for ASW/RCF at the lower level suggested as desirable by
NIOSH, i.e. 0.2 f/cc. This is reported to have come into effect on 3rd
August 2010 (RCFC, 2015b) though it appears that other States are
continuing to adhere to the existing OSHA (federal) limits.8.1.2. The American Conference of Governmental Industrial
Hygienists (ACGIH)
The ACGIH is a professional association of industrial hygienists
and practitioners of related professions, with headquarters in Cin-
cinnati, Ohio.
The ACGIH TLVeTWA for ASW/RCF is set at an intermediate
level between asbestos (0.1 f/cc) and other types of SVF (1.0 f/cc).
The recommended TLVeTWA of 0.2 f/cc for ASW/RCF reﬂects
concerns based on pleural and lung function abnormalities seen
among exposed cohorts, taken to indicate that the health risks of
RCF are closer to asbestos than other types of SVF. Similarly, an A2
(Suspected Human Carcinogen) notation is assigned for ASW/RCF,
based on the following: 1) ASW/RCF causes lung ﬁbrosis, lung
cancer, and mesothelioma in animals exposed via inhalation; 2)
these health effects resemble those of asbestos (a conﬁrmed human
carcinogen); and 3) ASW/RCF exposures in humans have been too
brief to date to allow an accurate assessment of the risks of lung
cancer and mesothelioma. There appears to be no published
detailed scientiﬁc rationale explaining the speciﬁc limit value
selected.
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In 1997, a European Technical Progress Committee decided that
the evidence from experimental animal studies was sufﬁcient to
warrant ASW/RCF being classiﬁed as what at that time was termed
an EU Category 2 carcinogen (i.e. a substance to be regarded as if it
were carcinogenic to humans)20 and the risk phase R49 ('may cause
cancer by inhalation') was applied.
Directive 97/69/EC of 5 December 1997 sets out the classiﬁca-
tions of two types of randomly-oriented MMMF:
(a) mineral wools; and
(b) RCFs (also special purpose ﬁbres (SPFs) which are not within
the scope of this paper).
The term “randomly-oriented” was applied to distinguish these
categories of MMMF from continuous ﬁlament ﬁbres, which are
generally thicker in diameter.
Under Directive 97/69/EC, mineral wools were classiﬁed as
Category 3 (now called Category 2 e suspected or possible) car-
cinogens and ASW/RCFs as Category 2 (now Category 1b e pre-
sumed) carcinogens. The classiﬁcation as a Category 2 (now 1b)
carcinogen applied to ﬁbres of a certain size only (with those
greater than 6 mm length-weighted geometric mean diameter be-
ing regarded as too large in diameter to be respirable and therefore
posing no carcinogenic hazard by inhalation). Mineral wools were
also exempted from classiﬁcation as carcinogenic if they met any of
four speciﬁed conditions set out in the Directive.8.2.1. SCOEL and DECOS
Assessments of the carcinogenicity of ASW/RCF have recently
been published by the European Scientiﬁc Committee on Occu-
pational Exposure Limits (SCOEL, 2011) and the Dutch Expert
Committee on Occupational Safety (DECOS, 2011). These are
notable for their consideration of the MoA of ASW/RCF and their
conclusions regarding thresholds and the establishment of no-
effect levels.
In considering the MoA, SCOEL acknowledged the well-
established fact (IARC, 2002) that chronic inﬂammation contrib-
utes to cancer development and concluded that inﬂammation is the
relevant mechanism explaining the effects of ASW/RCF in experi-
mental animals. Since lung inﬂammation is known to occur and
persist only at high doses, SCOEL were content to assume that the
basic mechanism of ﬁbre carcinogenicity involved a threshold, as
explained and described in a number of publications that have
evaluated and described this mechanistic principle of ﬁbre toxicity
and carcinogenicity (e.g. Greim et al., 2001; Schins, 2002; IARC,
2012). Moreover, the report elaborates how epidemiological
studies in workers of facilities located in the US, which started
ASW/RCF production in 1953, support the threshold concept of
ﬁbre carcinogenicity. Although originally workers were exposed to
relatively high ﬁbre concentrations of 10 ﬁbres/ml or more, no
additional lung cancer burden has been observed even more than
30 years after the onset of exposure (SCOEL, 2011). Since the latency
of asbestos-induced mesothelioma can be up to 50 years, the
relationship between RCF exposure and respiratory malignancies
has not been fully determined. However, RCF and rock wool have
similar airborne ﬁbre dimensions and persistence. Based on the
numerous existing cohort and case control studies, IARC (2002)20 Under the present EU Classiﬁcation, Labelling and Packaging Regulations 2008,
which contains the Globally Harmonised System (GHS) for classiﬁcation and
labelling, the designated carcinogen classiﬁcation is 1b (presumed human carcin-
ogen based on demonstrated animal carcinogenicity).concluded that there is no epidemiological evidence for the carci-
nogenicity (including mesothelioma induction) of rock wool. The
analogy with rock wool makes it reasonable to believe that in-
creases in lung cancer or mesothelioma incidence are unlikely to be
found in RCF-exposed workers (Greim et al., 2014).
On the basis of this epidemiological evidence, SCOEL concluded
that there was no evidence for exposure-related pulmonary ﬁbrosis
or cancer in ASW/RCF workers, and used ﬁndings on pulmonary
function, which provides sensitive parameters for the evaluation of
ASW/RCF exposure, to determine a no-effect level. Assuming a 45-
year exposure and average cumulative exposure of 147.9 (all
workers) or 184.8 f.mo/ml (workers >60 years old), SCOEL calcu-
lated averageﬁbre concentrations of 0.27 and 0.34 f/ml respectively.
Considering these values as no observed adverse effect levels, SCOEL
therefore proposed an OEL of 0.3 f/ml. According to SCOEL, the
epidemiological studies and the evidence that inﬂammation is the
primary underlying mechanism of ﬁbre carcinogenicity strongly
indicate that genotoxic effects observed in certain experimental
studies represents a secondary change arising from the induction of
reactive oxygen species (ROS) and, in the case of cytogenetic effects,
from the interaction of the ﬁbres with the spindle apparatus of the
cell. SCOEL thus evaluated ASW/RCF as ‘Group C’ e a genotoxic
carcinogen for which a practical threshold is supported.
Similarly the DECOS Committee considered the induction of
chronic inﬂammation to be the most plausible mechanism of
carcinogenic action of ASW/RCF, and also acknowledged that this
implies the existence of a threshold of effect. In addition, they
concluded that it is unlikely that ASW/RCF possesses stochastic
genotoxic properties via direct production of ROS, given its very low
iron content.
DECOS considered the number of observational studies report-
ing possible associations between occupational exposure to ASW/
RCF and cancer development in humans to be limited and
concluded that, overall, available data are insufﬁcient to draw a
conclusion whether or not ASW/RCF is carcinogenic to humans.
However, they concluded that, while not all were positive and other
factors were at play, the animal studies on ASW/RCF do indicate
carcinogenic activity. Their assessment was, therefore, that while
ASW/RCF should be presumed to be carcinogenic to man, this was
due to a non-genotoxic mechanism. Based on this conclusion, an
OEL of 1 f/ml (8hr TWA) was derived, based on a NOAEL of 25 f/ml
and a safety factor of 25 to take into account the seriousness of the
critical effect (cancer).8.2.2. The German approach to ASW/RCF
As mentioned earlier (Section 5.2.1), German authorities have
adopted a system (ERR) based on quantitative risk assessment in
which deﬁned levels of ‘acceptable risk’ are used to determine OELs
for carcinogens.
With respect to the regulatory implications for ASW/RCF, a
number of statements in TRGS 910 appear to imply that ‘carcino-
gens’ in the context of this approach include only those substances
that have been shown to have no threshold (i.e. are genotoxic).
Given that ASW/RCF has been argued by authoritative sources (e.g.
SCOEL, see above) to be either non-genotoxic or, at most, to show a
threshold effect as a result of secondary genotoxic changes, it can be
strongly argued that ASW/RCF should not be included as a carcin-
ogen within the meaning and intention of this approach. The
negative in vitro genotoxicity test results obtained for ASW/RCF2121 ‘Reverse mutation in ﬁve histidine-requiring strains of Salmonella typhimurium’.
Unpublished report for Thermal Ceramics UK Ltd by Covance Laboratories Ltd, UK.
May 2010. Study number 8215684. Cited in the REACH registration document for
ASW/RCF.
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non-genotoxic or secondary (ROS-induced) genotoxin and not
appropriate for consideration using the ERR approach.
The AGS document ‘ERR (exposure-risk relationship) for
aluminium silicate ﬁbres (see Section 5.2.1), as a consequence of
various questionable scientiﬁc and methodological approaches,
reaches the conclusion that certain types of MMMF e including
ASW/RCF e pose a carcinogenic risk the same order of magnitude
as crocidolite asbestos, a known human carcinogen. This runs
counter to the general scientiﬁc and regulatory consensus on ﬁbre
toxicity and is inconsistent with the occupational epidemiological
evidence which shows that ASW/RCFs are not associated with
elevated standard mortality ratios for either lung cancer or meso-
thelioma (Boffetta et al., 2014; Greim et al., 2014). In addition, TRGS
910 indicates that if acceptable concentrations cannot be deter-
mined by measurement, it is set at the limit of detection; this is the
case for ASW/RCF for which the ‘tolerance’ concentration has been
set at 0.1 f/ml. This conclusion and approach is certainly debatable.
As discussed earlier (Section 5.2.1), for substances such as RCF/
ASW for which a non-genotoxic or a threshold genotoxic mecha-
nism can be shown to be responsible for the carcinogenic process,
methods involving the deﬁnition of a no-effect level should be used
as the basis for setting limits, rather than approaches using calcu-
lated risk estimates.
As previously noted (Section 5.2.1), TRGS 558, referring to ASW/
RCF, states that ‘according to the current state of scientiﬁc knowl-
edge it is not possible to discount a risk of cancer when these ﬁbre
dusts are inhaled’. This runs counter to the arguments for a
threshold of response for ASW/RCF made by SCOEL and DECOS
(Section 8.2.1).
8.2.3. France
In France, AFSSET22 has derived a recommended occupational
exposure limit for ASW/RCF of 0.1 f/ml, based on the assumptions of
proven carcinogenicity in animal studies and of a mechanism of
toxicity that has no threshold in humans. Consequent to the
assumption of no threshold of effect, a linear model is applied to
establish a dose-response for low dose exposures, correlated to
units of excess risk. The risk values are based on a summary pre-
sented by Maxim et al. (2003). Determination of an OEL is done by
evaluation of the individual additional lung cancer risk and
applying societally acceptable risk values. The value of 0.1 f/ml for
an 8 h OEL corresponds to an excess risk for lung cancer, at 70 years
of age, of 5  104.
Like the German approach, the French methodology hinges on
the assumption that ASW/RCF is a non-threshold (genotoxic)
carcinogen, and hence is open to the same criticisms (see Section
8.2.1).
8.2.4. UK: Health and Safety Executive (HSE)
Directive 97/69/EC relating to the classiﬁcation, packaging and
labelling of dangerous substances, including ASW/RCF and other
mineral ﬁbres (see Section 8.2), was implemented in Great Britain
in 1999 by an amendment to the CHIP Regulations.
At a meeting of HSE's Advisory Committee on Toxic Substances
(ACTS) in March 2000, an HSE-commissioned report collating and
reviewing airborne ﬁbre concentrations generated in the manu-
facture, installation and removal of RCFs (ACTS/45/98/INF) was
reviewed (ACTS/05/2000). ACTS was asked to consider the feasi-
bility of setting a separate lower ‘maximum exposure limit’ (MEL)
for ASW/RCFs because of their carcinogenic potential. ACTS agreed22 Now ANSES e the French Agency for Food, Environmental and Occupational
Health & Safety.that HSE should carry out a Regulatory Impact Assessment (RIA) for
twoMEL proposals of 1 f/ml and 0.5 f/ml. HSE concluded that 1 f/ml
was practicable but that reduction to 0.5 f/ml was likely to have
more far-reaching implications, in particular for small companies,
some of which would ﬁnd this limit extremely difﬁcult to achieve,
and a MEL (now termed WEL) of 1 f/ml was adopted.
The current gravimetric and ﬁbre number WELs for ASW/RCF e
as listed in HSE guidance document EH40 e are 5 mg/m3 (total
inhalable dust) and 1 ﬁbre/ml respectively. Although in terms of
health effects, it is the concentration of respirable ﬁbres (f/ml) that
relates to effects in the deep lung (ﬁbrosis and carcinogenicity),
there is also a concern for the possibility of effects in the upper
airways that are more likely to relate to the total inhalable dust
concentrations. Hence, in occupational situations with the poten-
tial for generating high airborne dust levels (e.g. kilnwrecking), the
gravimetric limit offers a useful riskmanagement tool in addition to
the f/ml limit. However, in all circumstances, it is control to the f/ml
count that is the predominant requirement.
In the UK, the WEL for ASW/RCF is based on the notion of
reasonable practicality, which is not necessarily part of the OEL-
setting procedure in other countries, and unlike some other regu-
latory authorities HSE's approach does not involve prediction of
residual risk at the limit value.
A summary of different approaches to the risk assessment of
ASW/RCF is given in Table 2.
8.3. Other risk analyses of ASW/RCF
Drawing on both experimental (rat) and limited occupational
epidemiological data, Maxim et al. (2003) critically reviewed pre-
viously published quantitative risk assessments that derived
maximum likelihood estimates (MLE) for the incremental cancer
risk associated with a working lifetime exposure to a concentration
of 1 ﬁbre/ml of ASW/RCF; these historic estimates were noted to
vary between 4.1  106 and 3.4  103. The authors further
compared these with new estimates obtained using benchmark
dose (BMD) models, drawing on US EPA methods that gave MLE
estimates of approximately 2.4  104e6.7  104.
The authors noted that none of the quantitative risk assess-
ments performed on ASW/RCF have explicitly adjusted for possible
confounding from the effects of co-exposure to particles and ﬁbres
and, hence, may be regarded as somewhat conservative. When
historic assessments lacking adequate documentation or utilising
less favoured methodologies were excluded, the range of MLEs was
found to be 104e103, thus falling much closer to the estimates
obtained using a BMD approach. For all estimates, however, the
authors noted that the two greatest uncertainties were the as-
sumptions used to normalise lung burden and the potential for
confounding from co-exposures to particles (Maxim et al., 2003).
When considering the stringency of risk management that is to
be applied for the use of a substance in workplaces, it is important
for regulatory bodies to understand the nature and scale of health
impacts predicted to occur so that these may be balanced against
the socio-economic consequences of any regulatory measures. In
the case of the EC, a report by IOM to the European Commission, the
‘SHEcan’ Summary Report (IOM, 2011), has assessed the scale of the
potential health, environmental and socio-economic impacts that
would arise from amendment of the European Carcinogens and
Mutagens Directive (2004/37/EC) for a number of occupational
carcinogens, including ASW/RCF. Importantly, ASW/RCF was one of
eight that were shown to have ‘little or no baseline health impact’.
That is, there was little evidence for any signiﬁcant impact arising
from current or relatively recent exposures in the EU. The projected
number of cancer cases that might be attributed to occupational
exposure was less than about 10 per year for the whole EU
Table 2
Different jurisdictions’ approaches to ASW/RCF.
USA: NIOSH (REL e Recommended
exposure limit)
A pragmatic approach drawing on toxicological evidence from human and experimental studies but also considering
evidence on the extent to which ASW/RCF exposure could be controlled for various workplaces and activities. The
resultant REL of 0.5 f/ml is considered to be “achievable for most workplaces where RCFs or RCF products are manufactured,
used, or handled”. When considering the residual risk of lung cancer at this REL, an estimate of 0.073e1.2 per 1000 was
made by extrapolation from a number of published risk models. Because of uncertain mesothelioma risk at this level
NIOSH suggested that worker exposure should be reduced to 0.2 f/cm3 or below, the level at which lung cancer risk was
suggested to be 0.03e0.47 per 1000.
USA: ACGIH (TLV-TWA e Threshold limit
value-time weighted average)
The TLVeTWA for ASW/RCF is set at an intermediate level between asbestos (0.1 f/cc) and other types of SVF (1.0 f/cc).
The recommended TLVeTWA of 0.2 f/cc for ASW/RCF reﬂects concerns based on pleural and lung function abnormalities
seen among exposed cohorts that were taken to indicate that the health risks of RCF are closer to asbestos than other
types of SVF. Similarly, an A2 (Suspected Human Carcinogen) notation is assigned for ASW/RCF, based on the following:
1) ASW/RCF cause lung ﬁbrosis, lung cancer, andmesothelioma in animals exposed via inhalation; 2) these health effects
resemble those of asbestos (a conﬁrmed human carcinogen); and 3) ASW/RCF exposures in humans have been too brief
to date to allow an accurate assessment of the risks of lung cancer and mesothelioma. There appears to be no detailed
scientiﬁc rationale for the speciﬁc limit value selected.
EU: SCOEL Using epidemiological evidence, SCOEL concluded that there was no evidence for exposure-related pulmonary ﬁbrosis
or cancer in ASW/RCF workers, and used ﬁndings on pulmonary function to determine a no-effect level. Assuming a 45-
year exposure and average cumulative exposure of 147.9 (all workers) or 184.8 f.mo/ml (workers >60 years old), SCOEL
calculated average ﬁbre concentrations of 0.27 and 0.34 f/ml respectively. Considering these values as no observed
adverse effect levels, SCOEL therefore proposed an OEL of 0.3 f/ml. According to SCOEL, the epidemiological studies and
the evidence that inﬂammation is the primary underlying mechanism of ﬁbre carcinogenicity strongly indicate that
genotoxic effects observed in certain experimental studies represents a secondary change arising from the induction of
reactive oxygen species (ROS). SCOEL thus classiﬁed ASW/RCF as a genotoxic carcinogen with a practical threshold.
Netherlands: DECOS DECOS concluded that available human observational data are insufﬁcient to draw a conclusion whether ASW/RCF is
carcinogenic to humans. However, they determined that, with caveats, the animal studies on ASW/RCF do indicate
carcinogenic activity. Their conclusion was that ASW/RCF should be presumed to be carcinogenic to man through a non-
genotoxic mechanism. Based on this assessment, an OEL of 1 f/ml (8hr TWA) was derived, based on a NOAEL of 25 f/ml
and a safety factor of 25 to take into account the seriousness of the critical effect (cancer).
Germany: AGS German authorities have adopted a system based on quantitative risk assessment in which deﬁned levels of ‘acceptable
risk’ are used to determine OELs for carcinogens. The AGS document ‘ERR (exposure-risk relationship) for aluminium
silicate ﬁbres reaches the conclusion (based essentially on IP data) that certain types of MMMF e including ASW/RCF e
pose a carcinogenic risk the same order of magnitude as crocidolite asbestos e a known human carcinogen. Document
TRGS 521 establishes for SVF dusts a ‘trigger’ concentration (which drives the requirement for protective measures) of
50,000 ﬁbres/m3 e or 0.05 f/ml e which is equivalent to that for asbestos and far stricter than OELs applied to SVF by
other jurisdictions. However, TRGS 910 indicates that if acceptable concentrations cannot be determined by
measurement, it is set at the limit of detection; this is the case for ASW/RCF for which the ‘tolerance’ concentration has
been set at 0.1 f/ml.
France: AFSSET (now ANSES) AFSSET has derived a recommended occupational exposure limit for ASW/RCF of 0.1 f/ml, based on the assumptions of
proven carcinogenicity in animals and of a mechanism of toxicity that has no threshold in humans. A linear model is
applied to establish a dose-response for low dose exposures, correlated to units of excess risk. Determination of an OEL is
done by evaluation of the individual additional lung cancer risk and applying societally acceptable risk values. The value
of 0.1 f/ml for an 8hr OEL corresponds to an excess risk for lung cancer, at 70 years of age, of 5  104. The approach
hinges on the assumption that ASW/RCF is a non-threshold (genotoxic) carcinogen.
UK: HSE (ACTS) On the basis of health considerations, practicalities and costs, HSE recommends an airborne ﬁbre limit (WEL e
workplace exposure limit) for ASW/RCFs of 1f/ml (previously 2f/ml) expressed as an 8-h time-weighted average. HSE
also recommends the retention of the existing gravimetric limit of 5 mg/m3 (total inhalable dust) 8-h TWA, which offers
a useful risk management tool in occupational situations with the potential for high airborne dust levels. In all
circumstances, however, it is control to the f/ml count that is the predominant requirement.
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occupational exposure, based on worst-case assumptions, was also
low (in 2010, no attributable deaths in manufacturing and two
deaths in downstream users). Predictions of future mortality pat-
terns suggest that, by 2050, there would be none relating to
occupational ASW/RCF exposure. In considering the inﬂuence of
introducing an OEL of 0.1 or 1 ﬁbres/ml, it was found that there
would be no important impact on cancer deaths or registrations for
ASW/RCF. For both potential OELs, estimated disability-adjusted life
years (DALYs) decrease from 29 years in 2010 to zero years by 2060;
with no intervention there are two DALYs predicted in 2060. Whilst
IOM did not estimate mesothelioma risk (because the authors did
not believe that the human epidemiological data substantiates such
a risk), if it was assumed to be an impact, under worst case as-
sumptions there might be three times the number of cancers as
estimated. While this would increase the total health impact, the
authors concluded that this would not change their overall ﬁnding
that, for ASW/RCF, an EU-wide OEL of 1.0 ﬁbres/ml could likely be
met through greater uptake of currently available techniques by
industry, with associated costs being relatively low. Only a small
health beneﬁt was associated with this OEL, valued at up to
V1e2 million in total over the period 2010e2069. This contrastswith estimates based on an OEL of 0.1 ﬁbres/ml, which would have
much more signiﬁcant costs for industry. Achieving this exposure
limit would require a degree of automation and enclosure that was
considered unlikely to be feasible, especially for certain down-
stream users, and the associated compliance costs were estimated
at V60 to V140 million (2010e2069) e to achieve minimal health
gains.
8.4. Existing OELs for ASW/RCF worldwide
Before considering existing OELs for ASW/RCF, it is important to
appreciate that there has been, and continues to be, signiﬁcant
improvement in occupational hygiene practices across most in-
dustrial sectors. Hence occupational exposure to chemicals has
shown a steady decrease since the 1970's. For example, Creely et al.
(2007), looking at a range of industries, reported the level of
inhalation exposure for almost all chemicals to have decreased
annually by 1e32% (median 8%) while speciﬁcally for ﬁbres, the
annual declinewas as much as 32%. Also, in Finland, by 2008 overall
inhalation exposure to chemicals had fallen to 41% of the 1970 value
and prevalence of high exposure to asbestos had decreased from
4.1% to <0.1% over the same period (Kauppinen et al., 2013).
Table 3
Occupational (and other relevant) exposure limits established for ASW/RCF.
Jurisdiction OEL or other control value (f/mla)
Australia 0.5 (2 mg/m3 inhalable dust)
Austria 0.5 (10 mg/m3 total dust)
Belgium 0.5
Canada 0.2e1.0 (territories differ)
Czech Republic 1.0
Denmark 1.0 (5 mg/m3 total dust)
Finland 2.0 (glass wool & mineral wool 10 mg/m3)
France 0.1 (general dust, mineral wool 10 mg/m3)
Germany 0.1 (tolerance level)
Italy 0.2
The Netherlands 0.5
New Zealand 1.0
Japan 1.0
Norway 0.1
Poland 1.0
Slovakia 2.0
Spain 0.5
Sweden 0.2
Switzerland 0.25
United Kingdom 1.0
United States of America e NIOSH 0.5
OSHA 0.5
ATSDR 0.03 f/cm3 (MRL e general public)
ACGIH 0.2
SCOEL Recommendation 0.3
Notes:
OEL e Occupational exposure limit.
ae Value given as ﬁbres per ml unless otherwise indicated; where sources quote different limits, lowest cited is
presented.
MRL e Minimal risk level.
SCOEL e Scientiﬁc Committee on Occupational Exposure Limits.
ATSDR e Agency for Toxic Substances Disease Registry.
NIOSH e National Institute for Occupational Safety and Health.
OSHA e Occupational Safety and Health Administration.
ACGIH e American Conference of Governmental Industrial Hygienists (no legal status).
f/ml e ﬁbres per ml.
Sources: Maxim and Utell (2014); SCOEL (2011); NIOSH (2006).
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limits (OELs) for ASW/RCF, and other organizations have produced
recommended or guideline limits for worker exposure. Examina-
tion of currently established limits shows considerable differences
between authorities regarding the level of control considered
necessary for the protection of workers. Established OELs vary by
an order of magnitude (see Table 3), with Germany, France and
Norway being notable outliers. In part this reﬂects the time when a
particular OEL was established or last reviewed, though there also
exist fundamental differences in the approaches taken across the
jurisdictions in the assessment of risk posed by these materials, as
discussed in this paper. Despite this, it is generally apparent that
there has been an ongoing tendency to set increasingly more
stringent occupational hygiene standards over recent decades. For
example, a recent (2011) proposal of 0.3 f/ml by the EC's SCOEL
committee, which is based on pulmonary function changes, is not
dissimilar to the 0.5 f/ml level established by NIOSH and OSHA or
the 0.2 f/ml proposed by ACGIH (SCOEL, 2011). As might be ex-
pected, where exposure standards for the general public have been
established (e.g. in the USA), lower values are adopted, as can be
seen from the MRL of 0.03 f/ml set by the ATSDR, which takes ac-
count of different exposure durations. In any event, even if a rela-
tively high OEL still exists in a particular jurisdiction, workers there
may actually experience somewhat lower exposures due to in-
dustry establishing a ‘recommended’ in-house exposure limit.2323 See “What are the recommended maximum ﬁbre exposure levels?” in the
‘Q&A’ section of the ECFIA website at www.ecﬁa.eu/qa.htm.The intention is that this limit, 0.5 f/ml, should be applied in the
absence of any more stringent limit mandated by the competent
authority. In deriving the recommendation, industry based their
considerations on prudence and feasibility criteria, rather than a
speciﬁc indicator of a particular risk at a higher exposure (Maxim
and Utell, 2014).249. Discussion
It is important for stakeholder conﬁdence that transparent and
consistent approaches to risk assessment are adopted worldwide.
Without this, widely varying OELs will continue to be derived and
applied, which is an unsatisfactory and confusing situation for
manufacturers, workers and businesses alike (see IEH/ICMM,
2006). For ASW/RCF it has been shown that OELs vary by more
than an order of magnitude, due at least in part to certain countries
adopting risk assessment procedures that are out of line with other
country's approaches and which give rise to much lower values.
Table 4 illustrates the differing rationales/procedures applied by
various organisations in deriving limit values for ASW/RCF.
Recent authoritative assessments by various national and in-
ternational bodies or groups (e.g. SCOEL, 2011; DECOS, 2011) have
consistently determined that ASW/RCF is a threshold carcinogen
(either non-genotoxic or a secondary genotoxin) and that it is24 Note: In a recent update to the REACH registration dossier for ASW/RCF, in-
dustry presents a calculated DNEL of 1.62 f/ml, based on the procedures and
assessment factors recommended in ECHA guidance document R.8.
Table 4
Summary of applied procedures/rationales for some derived limit values.
Source Selected key
study type
Study target organ,
endpoint
Human
endpoint
Anticipated risk
level
Limit value
[f/ml]
Strengths and weaknesses of approach
adopted
SCOEL (EU) Epidemiology Lung, pulmonary
function
Chronic
inﬂammation
Health-based
threshold
0.3 Strengths: Science-based (considers
possibility of threshold/non-threshold
mechanisms, uses physiologically-
relevant data, uses epidemiological
evidence); transparent; conservative
assessment factors used to address
uncertainties; practical to monitor
compliance.
Weaknesses: None identiﬁed
DECOS
(Netherlands)
Animal inhalation Lung, cancer Cancer Health-based
threshold
1.0 Strengths: Science-based (considers
possibility of threshold/non-threshold
basis, considers epidemiological
evidence); transparent; provides
reasonably conservative safety factor
for cancer risk; practical to monitor
compliance.
Weaknesses: Animal-based; does not
incorporate epidemiology data;
established value above that commonly
achievable by industry
HSE (UK)* Not known/Not
speciﬁed
N/A Cancer/Fibrosis Health-based
threshold
1.0 Strengths: Pragmatic
Weaknesses: opaque derivation and
therefore not open to peer review;
established value above that commonly
achievable by industry
NIOSH (USA) Animal inhalation Lung, cancer Cancer Risk  1:1000
(extrapolation)
0.5 Strengths: Science-based (considers
animal and epidemiological data,
possibility of threshold/non-threshold
basis, and also addresses non-cancer
endpoints); practical to monitor
compliance
Weakness: Established on voluntary
not regulatory-backed basis, in
collaboration with industry (which may
be seen as a weakness by some
stakeholders)
ACGIH (USA) Not known/not
speciﬁed
N/A Cancer Health-based
threshold
0.2 Strength: Highly conservative limit
Weakness: Uncertain/opaque
derivation not open to peer-review
AGS (Germany) Animal IP
injection
Peritoneum, cancer Cancer Risk  4:1000
(extrapolation)
0.1 (tolerance
level)
Strength: Highly conservative limit
Weaknesses: Strictly animal-based;
does not consider epidemiological
evidence; uses non-physiological route;
does not distinguish between threshold
and non-threshold mechanisms; based
on limited data; adopts unvalidated
assumptions; adopts not strictly
scientiﬁca risk values
AFSSET e now
ANSES (FR)
Based on risk estimates review
by Maxim et al. (2003)
N/A Cancer Risk  5:10,000
(extrapolation)
0.1 Strength: Highly conservative limit
Weaknesses: Assumes non-threshold
effect with linear dose-response; based
on limited dataset, adopts not strictly
scientiﬁc1 risk values; does not consider
epidemiological evidence
a i.e. values considered ‘societally-acceptable’ rather than based on scientiﬁc concepts.
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health risk assessment approaches. This opinion is supported by
experimental data cited in the REACH registration dossier for ASW/
RCF, derived from research commissioned at an independent
quality-assured toxicology testing facility to determine the geno-
toxic potential of ASW/RCF.13 In regulatory-compliant mutagenicity
tests using different histadine-dependent strains of Salmonella
typhimurium (TA98, TA100, TA1535, TA1537 and TA102), ASW/RCF
at up to 5000 mg/plate did not induce gene mutations. A similarly
compliant in vitro cytogenicity assay using duplicate cultures of
Chinese hamster ovary cells, investigating ASW/RCF up to and
including the maximum practicable concentration of 1000 mg/mL,
did not induce micronulei in either pulse or continuous exposure
regimes. These results indicate that ASW/RCF has no demonstrablemutagenic activity in standard test systems for this endpoint.
Moreover, the independent ‘SHEcan’ report (IOM, 2011) provides
strong evidence that current conditions of use of ASW/RCF in
Europe do not pose a signiﬁcant carcinogenic risk to workers.
As argued by SCOEL and previously suggested by IARC (2002), it
is most likely that inﬂammation is the underlying effect of ﬁbre
carcinogenicity and that the genotoxic effects observed in certain
studies are secondary, resulting from the induction of reactive ox-
ygen species and, in the case of cytogenetic effects, from the
interaction of the ﬁbres with the spindle apparatus. This is the
reason that SCOEL classiﬁed ASW/RCF as a genotoxic carcinogen for
which a practical threshold is supported, and why the assumption
in the ERR-MMMF document that ASW/RCF (and other MMMFs)
are non-threshold carcinogens, with associated application of
P. Harrison et al. / Regulatory Toxicology and Pharmacology 73 (2015) 425e441 439straight-line dose responses for carcinogenicity, is not supported by
the currently available scientiﬁc and medical evidence.
We argue here particularly that the ERR approach is not
appropriate for threshold carcinogens, and that ASW/RCF is such a
substance. One premise for the assumption of a carcinogenic
threshold is the fact that ASW/RCF is non-genotoxic. Moreover,
there are several important factors clearly distinguishing ASW/RCF
and other MMMFs from asbestos that are important in determining
risk, including ﬁbre dimension, the propensity to fracture trans-
versely, and biopersistence. These considerations caution against
the assumption emade by the German AGS e that MMMF and the
various types of asbestos are equivalent in their carcinogenic po-
tential. Several studies in ASW/RCF workers have shown that ASW/
RCF has no demonstrable carcinogenicity in humans (SCOEL, 2011;
Walker et al., 2012a, b; Boffetta et al., 2014; Greim et al., 2014),
providing important data challenging the ERR approach for syn-
thetic mineral ﬁbres. It certainly seems unlikely that the results
from these studies are what would be expected for a non-threshold
carcinogen, which the German authorities hold ASW/RCF to be.
Speciﬁcally, the ERR method may be criticised as unsuited for
use with threshold carcinogens, and the attempts to apply it to
ASW/RCF and MMMF more generally contain critical scientiﬁc
ﬂaws. In particular, the application is weakened by the reliance on
IP rather than inhalation study data when calculating risk and the
high degree of uncertainty associated with the various assumptions
and calculations undertaken.
It would be highly advantageous for risk assessment approaches
for synthetic mineral ﬁbres e and hence their OELs e to be globally
harmonised, taking into account the three principal factors that
drive the derivation of an OEL, namely: 1) determination of the POD
from the most relevant study (animal or human); 2) application of
appropriate ‘assessment factors’ to the POD; and 3) use of the
availableMoA data that will determinewhether a threshold or non-
threshold approach should be used. Currently, different jurisdic-
tions have different systems and approaches to setting OELs. In the
UK, for example, aspects of practicality and enforceability are often
taken into account while other countries may simply set precau-
tionary or aspirational targets for the future. We suggest that all
OEL-setting procedures should be transparent, based on the three
above-mentioned toxicological principles, and should explicitly
indicate the degree to which considerations of precaution and/or
practicality are incorporated into the process.
For the global harmonisation of OELs it is clearly important that
the processes, principles and decisions reached when developing
standards must be sufﬁciently transparent to enable comparability
and understanding of differences between the approaches.25 This
should result in a higher uniform quality and greater conﬁdence in
the robustness of the OELs amongst the regulatory community,
industry and the labour force. It is understood, however, that
achieving harmonisation may prove difﬁcult due to the varying
remits and underlying philosophies of standard-setting bodies, and
because of differences in scientiﬁc belief and approaches that exist
worldwide (IEH/ICMM, 2006). Nonetheless, there are some
fundamental activities that can and should be coordinated and
harmonised, as set out in detail in the IEH/ICMM report on the
setting and use of occupational exposure limits (IEH/ICMM, 2010).
A principal tenet of these recommendations, which we fully
endorse, is the documentation and publication of all the key steps
in the standard-setting process. Fortunately, a degree of25 The approach adopted by the EU-LCI Working Group that sets emission stan-
dards for building products (Kephalopoulos et al., 2014) is an excellent example of a
scientiﬁcally valid, transparent and fully documented methodology that can act as a
model for other bodies tasked with setting health based exposure limits.harmonisation in the use of assessment factors is already being
achieved in Europe through the publication of recommended
default values for use in establishing DNEL values under the REACH
regulations (ECHA, 2012b). Achieving success in the harmonisation
of OELs will require considerable active cooperation and informa-
tion sharing amongst regulatory bodies as well as the participation
of relevant stakeholders, but this is a goal worth striving for.
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